|
Prelude Therapeutics Incorporated (PRLD) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Prelude Therapeutics Incorporated (PRLD) Bundle
تبسيط تقييم Prelude Therapeutics Incorporated (PRLD) مع هذه الآلة الحاسبة DCF القابلة للتخصيص! يتميز بيانات REAL Prelude Therapeutics Incorporated (PRLD) ومدخلات التنبؤ القابلة للتعديل ، يمكنك اختبار السيناريوهات وكشف القيمة العادلة المسبقة (PRLD) في الدقائق.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -27.7 | -58.2 | -112.8 | -122.2 | -131.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .4 | .5 | 2.2 | 3.0 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -28.1 | -58.8 | -115.1 | -125.3 | -132.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 18.9 | 218.3 | 291.2 | 201.7 | 232.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.0 | 3.9 | 7.8 | 6.8 | 4.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.8 | -.6 | -2.3 | -3.0 | -3.5 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -28.1 | -58.8 | -114.1 | -116.5 | -132.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -26.5 | -56.9 | -110.3 | -117.5 | -136.8 | -4.6 | .0 | .0 | .0 | .0 |
| WACC, % | 8.73 | 8.73 | 8.72 | 8.65 | 8.73 | 8.71 | 8.71 | 8.71 | 8.71 | 8.71 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -8 | |||||||||
| Equity Value | 4 | |||||||||
| Diluted Shares Outstanding, MM | 60 | |||||||||
| Equity Value Per Share | 0.07 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Prelude Therapeutics Incorporated’s (PRLD) financial data pre-loaded to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive PRLD Data: Pre-loaded with Prelude Therapeutics' historical financials and future projections.
- Customizable Assumptions: Modify growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Adaptive Valuation Framework: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- Intuitive Interface: Designed for ease of use, catering to both experienced professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based PRLD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Prelude Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis decisions.
Why Choose This Calculator for Prelude Therapeutics (PRLD)?
- Accuracy: Leverages real Prelude Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs to fit their needs.
- Time-Saving: Eliminate the complexities of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and attention to detail expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling knowledge.
Who Should Use This Product?
- Investors: Accurately assess Prelude Therapeutics' (PRLD) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Prelude Therapeutics (PRLD).
- Consultants: Easily customize the template for valuation reports tailored to clients involving Prelude Therapeutics (PRLD).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Prelude Therapeutics (PRLD).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to Prelude Therapeutics (PRLD).
What the Template Contains
- Pre-Filled Data: Includes Prelude Therapeutics Incorporated’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess Prelude Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing key valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.